視丘下部性肥胖 - 開發平台分析:2023年

本報告提供視丘下部性肥胖的開發平台的相關調查，第一階段，第二階段，第三階段的開發平台趨勢，市場上競爭情形，法律規範趨勢，開發平台的藥物簡介等彙整資訊。

目錄

概要

視丘下部性肥胖的標的

• 簡介
• 視丘下部性肥胖的流行病學與原因
• 視丘下部性肥胖的病理學
• 視丘下部性肥胖的治療方法
• 治療流程

視丘下部性肥胖的各階段開發平台分析

• 視丘下部性肥胖的發病- 概要
• 開發中產品，各開發階段
• 視丘下部性肥胖的競爭情形，各相
• 開發中產品，各企業
• 視丘下部性肥胖的單劑療法和聯合治療的臨床試驗
• 開發中產品，各作用機制
• 視丘下部性肥胖臨床及法規計劃
• 後期階段的簡介的比較概要

視丘下部性肥胖症的授權，收購，及合作契約

視丘下部性肥胖開發平台的形勢

• 視丘下部性肥胖開發平台的藥物簡介

第Ⅲ相

• Setmelanotide(Rhythm Pharmaceuticals)
• Exenatide(AstraZeneca)

第二階段

• Tesomet (Saniona)

第一階段

• GT-001(Gila Therapeutics, Inc)

前臨床

• ENT-03(Enterin Inc)
• TRP-8802(Tryp Therapeutics)

視丘下部性肥胖的SWOT分析

附錄

The Hypothalamic Obesity report covers the Hypothalamic Obesity market opportunity providing Key Competitive Analysis, 6 Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. In addition, our report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, mechanism of action, intervention types. The Hypothalamic Obesity report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Hypothalamic obesity (HyOb) is a complex medical condition that can arise from the development of rare brain tumors or other forms of hypothalamic injury. Among the tumors that can give rise to HyOb, craniopharyngioma is a noteworthy example. Hypothalamic obesity is characterized by an abnormal hypothalamus function, a key aspect of which is its involvement in satiety and food intake regulation. Notably, damage to the ventromedial nucleus of the hypothalamus bilaterally can lead to a syndrome of HyOb that is typified by hyperphagia and obesity, as well as other endocrinal and neurological manifestations.

In this report, Mellalta Meets provides an in-depth analysis of Hypothalamic Obesity pipeline covering Phase III , Phase II & Phase I Pipeline Analysis Overview, Pipeline Products by Stage of Development, Hypothalamic Obesity Competitive Landscape Distinguished by Phase & Route and moleucle type, Clinical Pipeline Products by Company, Hypothalamic Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Hypothalamic Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are 6 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are AstraZeneca, Rhythm Pharmaceuticals, Saniona, Gila Therapeutics, which have robust clinical pipelines of Hypothalamic Obesity candidates.

As per analysis, the development pipeline is full of molecules like small molecules, and peptides.

Key Highlights of the Hypothalamic Obesity Report

• The Hypothalamic Obesity segment is dominated by the Phase 3 and pre-clinical assets (XX each) which represent XX% of the total development followed by XX each asset in Phase 1 and Phase 2 representing XX% of each of the pipeline development in Hypothalamic Obesity.

• The hypothalamic obesity treatment pipeline is marked by a strong presence of US-based biotech companies, accounting for an impressive XX% of all clinical-stage hypothalamic obesity therapies, followed by UK, Canada and Denmark with XX%.

• Hypothalamic Obesity pipeline landscape includes 100% of Monotherapy trials.

• The Hypothalamic Obesity segment is split equally between the pre-clinical and Phase 3 assets (2-2 each), phase 1 assets (2), and Phase 2 assets (2).

Report Coverage:

• Indication Prioritisation: Hypothalamic Obesity market potential based on Indications.

• Business Transactions & Strategies: Key collaborations and deal values

• Hypothalamic Obesity Pipeline Development: Product Profiles, Clinical Trials & Results

• Hypothalamic Obesity Acquisition Targets

• Hypothalamic Obesity Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The Hypothalamic Obesity Target BACKGROUND

• Introduction
• Epidemiology & Causes of hypothalamic obesity
• Pathophysiology of Hypothalamic Obesity
• Treatment Approach of Hypothalamic Obesity
• Treatment Algorithm

Hypothalamic Obesity PIPELINE ANALYSIS by Phases

• Hypothalamic Obesity Development - Overview
• Pipeline Products by Stage of Development
• Hypothalamic Obesity Competitive Landscape by Phases
• Pipeline Products by Company
• Hypothalamic Obesity Monotherapy & Combinations Clinical Trials
• Pipeline Products by MOA
• Hypothalamic Obesity Clinical & Regulatory Timelines
• Late-Stage Profiles Comparisons At-a-glance

Hypothalamic Obesity LICENSING, ACQUISITION, AND COLLABORATION DEALS

• Hypothalamic Obesity Licensing, Acquisition, and Deal values
• Hypothalamic Obesity Licensing by Transaction type and total amount size by Phases

Hypothalamic Obesity Pipeline Landscape

• Hypothalamic Obesity Pipeline Drug Profiles

Phase III

• Setmelanotide (Rhythm Pharmaceuticals)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Exenatide (AstraZeneca)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase II

• Tesomet (Saniona)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase I

• GT-001 (Gila Therapeutics, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Preclinical

• ENT-03 (Enterin Inc.)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• TRP-8802 (Tryp Therapeutics)
  • Product Profile & Description
  • Collaborations
  • Other Developments

Hypothalamic Obesity SWOT Analysis

Appendix

• About us